drug discovery

July 25, 2023

nference and Vanderbilt University Medical Center sign agreement to advance real-world evidence generation in complex disease populations

nference, a science-first software company transforming healthcare by making biomedical data computable, and Vanderbilt University Medical Center have announced a strategic agreement aimed at advancing research through the deployment of nference’s state-of-the-art federated clinical analytics platform. By leveraging the power of federated AI and machine learning, this collaboration will expand clinical insights in key research areas.

By VUMC News and Communications
July 11, 2022

A speedier treatment for depression?

Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.

By Paul Govern
May 1, 2018

Looking beyond the ‘magic bullet’ approach to drug discovery

Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.

By VUMC News and Communications
April 5, 2018

Nashville Biosciences created to leverage wealth of data

Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.

By Bill Snyder
close up of mans arm as he receives chemotherapy infusion
March 14, 2018

Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.

By Bill Snyder
Istock image of neurons in the brain
January 8, 2018

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

By Bill Snyder
September 20, 2017

Goal of new tissue-chip research is to assess efficacy of novel epilepsy drugs

An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.
By VUMC News and Communications
September 11, 2017

Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
By VUMC News and Communications
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
By Bill Snyder
May 25, 2017

Vanderbilt, Ono Pharmaceutical extend drug discovery agreement

Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.
By VUMC News and Communications
April 3, 2017

Fighting fungal infections

A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments.
By Leigh MacMillan
December 27, 2016

Investigational new drug for Alzheimer’s scheduled for first study in humans

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
By Craig Boerner
June 23, 2016

VU takes key role in cancer drug discovery consortium

Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.
By Leigh MacMillan
1 2 3